Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Kymera Therapeutics will present poster titled "Targeted Protein Degradation Beyond Oncology,” and share recent data related to the company’s IRAK4 program including findings from the company’s non-interventional trial in hidradenitis suppurativa (HS) patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2020
Details:
Kymera expects to file an IND for KT-474, an orally bioavailable IRAK4 degrader, in the 1H 2021. If approved, the company will initiate a Phase 1 trial in adult healthy volunteers and hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
